Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant SARS-CoV-2 B.1.1.529 variant vaccine (adenovirus type 5 vector)
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Inhalation
01
Overview
The recombinant SARS-CoV-2 B.1.1.529 variant vaccine (adenovirus type 5 vector) is a viral vector vaccine developed to provide targeted protection against the Omicron variant of COVID-19. It utilizes a replication-deficient adenovirus type 5 (Ad5) platform to deliver the genetic sequence of the SARS-CoV-2 spike protein specifically from the B.1.1.529 (Omicron) lineage. Developed by CanSino Biologics in collaboration with the Chongqing Center for Disease Control and Prevention and the Academy of Military Medical Sciences, the vaccine is designed to induce both humoral and cellular immune responses. It has been investigated for administration via both intramuscular injection and mucosal inhalation, with the latter intended to stimulate respiratory tract immunity and potentially reduce transmission. This candidate represents a variant-adapted update to the original Ad5-nCoV (Convidecia) vaccine.
- Brand names
- Convidecia Omicron
- Other names
- recombinant COVID-19 vaccine (adenovirus type 5 vector) expressing the spike protein of the SARS-CoV-2 Omicron variantAd5-vectored Omicron vaccineAd-5-vectored Omicron vaccineAd 5-vectored Omicron vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant SARS-CoV-2 B.1.1.529 variant vaccine (adenovirus type 5 vector).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant SARS-CoV-2 B.1.1.529 variant vaccine (adenovirus type 5 vector).